LAHORE: The Government of Punjab has ordered the immediate recall of five pharmaceutical products after provincial drug testing laboratories declared them substandard and adulterated, raising concerns over their quality and safety.
According to a public notice issued by the Directorate of Drugs Control, Punjab, on November 13, 2026, the Provincial Quality Control Board has directed the withdrawal of the affected medicine batches from the market following laboratory testing.
The recalled products include Injection Dormicum, Injection Davilax, Injection Zeftrox, Injection PSOL 2mL and Injection PSOL 10mL.
The notice identified two batches of Injection Dormicum (47447 and 47661), manufactured by Martin Dow Marker Ltd., as substandard due to the presence of visible particulate matter.
Injection Davilax, batch number DD1126, manufactured by Unison Chemical Works, was declared adulterated.
Meanwhile, Injection Zeftrox, batch number 677, manufactured by Zafa Pharmaceutical Laboratories (Pvt.) Ltd., and Injection PSOL 2mL, batch number AK164, manufactured by Pharmasol Private Ltd., were declared substandard following sterility testing.
Another product, Injection PSOL 10mL, batch number VL277, manufactured by Pharmasol Private Ltd., was also declared substandard due to visible particulate matter.
The Directorate of Drugs Control has directed the manufacturers and marketing authorization holders of the affected products to immediately initiate recall procedures and provide complete distribution records of the identified batches.
The companies have also been instructed to conduct detailed root-cause analyses and prepare Corrective and Preventive Action (CAPA) plans. Relevant documents are to be submitted to the concerned drug regulatory authorities.
Pharmacies, medical stores, wholesalers, distributors and healthcare facilities across Punjab have been directed to immediately stop dispensing the affected medicine batches.
They have also been instructed to report their remaining stock and consumption records to the respective area Drug Inspectors or Drug Inspectors of Health Facilities.
The Directorate further directed Punjab’s drug regulatory authorities to strengthen surveillance across the pharmaceutical supply chain and take appropriate regulatory action in accordance with the Drugs Act, 1976, and the DRAP Act, 2012.
In its advisory to consumers and the general public, the Directorate has urged patients to immediately stop using the identified batches, warning that their continued use may pose health risks.
Healthcare professionals and consumers have also been advised to report any adverse drug reactions associated with the affected products to the Provincial Pharmacovigilance Centre at the Directorate of Drugs Control, Punjab.
The recall notice is part of the provincial government’s regulatory action to address pharmaceutical quality concerns and protect public health.
Comments
Comments (0)
Security Check
Please complete the captcha to verify you are human.